Citigroup
AURA icon

Citigroup’s Aura Biosciences AURA Stock Holding History

Citigroup’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
23,432
+10,950
+88% +$78.3K ﹤0.01% 4430
2026
Q1 		$83.5K Sell
12,482
-22,409
-64% -$129K ﹤0.01% 4346
2025
Q4 		$190K Buy
34,891
+29,457
+542% +$175K ﹤0.01% 4026
2025
Q3 		$33.6K Sell
5,434
-8,575
-61% -$56.1K ﹤0.01% 4619
2025
Q2 		$87.7K Sell
14,009
-18,856
-57% -$110K ﹤0.01% 4467
2025
Q1 		$193K Sell
32,865
-2,876
-8% -$21.8K ﹤0.01% 4227
2024
Q4 		$294K Buy
35,741
+1,841
+5% +$17.3K ﹤0.01% 4161
2024
Q3 		$302K Buy
33,900
+23,488
+226% +$201K ﹤0.01% 4075
2024
Q2 		$78.7K Buy
10,412
+3,727
+56% +$27.3K ﹤0.01% 4331
2024
Q1 		$52.5K Buy
6,685
+2,669
+66% +$22.1K ﹤0.01% 4595
2023
Q4 		$35.6K Sell
4,016
-102,410
-96% -$867K ﹤0.01% 4698
2023
Q3 		$955K Sell
106,426
-42,070
-28% -$453K ﹤0.01% 2555
2023
Q2 		$1.83M Sell
148,496
-367,546
-71% -$3.93M ﹤0.01% 2302
2023
Q1 		$4.79M Buy
516,042
+370,338
+254% +$3.85M ﹤0.01% 1530
2022
Q4 		$1.53M Sell
145,704
-4,036
-3% -$51.4K ﹤0.01% 2252
2022
Q3 		$2.71M Buy
149,740
+26,552
+22% +$402K ﹤0.01% 1929
2022
Q2 		$1.75M Buy
123,188
+122,969
+56,150% +$2.03M ﹤0.01% 2206
2022
Q1 		$5K Sell
219
-1,586
-88% -$30.2K ﹤0.01% 5794
2021
Q4 		$31K Buy
+1,805
New +$32.3K ﹤0.01% 5250

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citigroup's AURA Position: Q2 2026 in Review

Citigroup increased its Aura Biosciences (AURA) stake by 88% in Q2 2026, buying an estimated $78.3K and bringing the position to 23,432 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #4430.

Citigroup first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.79M in Q1 2023. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Citigroup held 23,432 shares of Aura Biosciences worth $166K as of Q2 2026.
  • Citigroup bought 10,950 Aura Biosciences shares in Q2 2026, an estimated $78.3K.
  • Aura Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4430 holding.
  • Citigroup first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Citigroup's Aura Biosciences position peaked at $4.79M in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.